{"title": "Drug combination may become new standard treatment for advanced kidney cancer", "title_detail": {"type": "text/plain", "language": null, "base": "https://www.sciencedaily.com/rss/health_medicine/pharmaceuticals.xml", "value": "Drug combination may become new standard treatment for advanced kidney cancer"}, "links": [{"rel": "alternate", "type": "text/html", "href": "https://www.sciencedaily.com/releases/2019/02/190217115910.htm"}], "link": "https://www.sciencedaily.com/releases/2019/02/190217115910.htm", "summary": "A combination of two drugs -- one of them an immunotherapy agent -- could become a new standard, first-line treatment for patients with metastatic kidney cancer, results from a phase 3 clinical trial suggest.", "summary_detail": {"type": "text/html", "language": null, "base": "https://www.sciencedaily.com/rss/health_medicine/pharmaceuticals.xml", "value": "A combination of two drugs -- one of them an immunotherapy agent -- could become a new standard, first-line treatment for patients with metastatic kidney cancer, results from a phase 3 clinical trial suggest."}, "published": "Sun, 17 Feb 2019 11:59:10 EST", "published_parsed": [2019, 2, 17, 16, 59, 10, 6, 48, 0], "id": "https://www.sciencedaily.com/releases/2019/02/190217115910.htm", "guidislink": false}